文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

CAR-NK细胞疗法治疗血液系统恶性肿瘤

CAR-NK cell therapy for hematological malignancies.
PubMed 文献 · Blood Adv · 2026-01-01

该综述总结CAR-NK细胞疗法的工程化趋势与临床进展,指出其安全性优于CAR T、可异体即用且无需预先致敏,多项临床试验显示显著疗效且无严重不良反应,同时讨论NK细胞体内持久性、代谢瓶颈与免疫抑制所致耗竭等挑战,并介绍早期临床试验管线。

要点

  • CAR-NK细胞安全性优于CAR T,可异体即用、易于规模化生产。
  • 多项临床试验显示对血液肿瘤有显著疗效且无严重不良反应。
  • 主要挑战包括体内持久性、代谢瓶颈与肿瘤免疫抑制致NK细胞耗竭。

核心结论

  • CAR-NK细胞疗法在血液肿瘤中显示显著疗效与较好安全性,具有变革潜力,但持久性与免疫抑制等挑战仍需解决。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • CAR-NK细胞来源于多种来源,已在多项临床试验中用于血液肿瘤,显示显著治疗反应和疗效且无严重不良反应。
  • CAR-NK细胞疗法面临的局限包括NK细胞体内持久性挑战、代谢瓶颈以及肿瘤劫持免疫抑制机制导致NK细胞耗竭。

临床怎么用

  • CAR-NK细胞可作为血液肿瘤的异体即用型细胞治疗选择,安全性优于CAR T且无需预先致敏。

局限性

  • 综述指出NK细胞体内持久性、代谢瓶颈和肿瘤免疫抑制致NK细胞耗竭是当前主要局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR)-natural killer (NK) cells represent a novel cell therapy platform distinguished from CAR T cells by their more favorable safety profile, easier off-the-shelf allogeneic manufacturing and consequent scalability, and their innate cytotoxicity without needing previous sensitization. CAR-NK cells derived from a variety of sources have been used against hematologic malignancies in several clinical trials, showing significant therapeutic responses and efficacy without severe adverse effects. Limitations that are being addressed in CAR-NK cell therapy include challenges regarding NK cell persistence in vivo, metabolic bottlenecks, and tumor-coopted immunosuppressive mechanisms that induce NK cell exhaustion. This review synthesizes current trends and innovations in CAR-NK cell engineering, examines the biological and technical challenges encountered in the clinical setting, outlines targeted preclinical approaches being implemented, and introduces recent early phase clinical trials in the pipeline. Summatively, we highlight the rapidly advancing and transformative potential of CAR-NK cell therapy for treating hematological cancers.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Manzar GS, Hasan MF, Moore M, et al. CAR-NK cell therapy for hematological malignancies. Blood Adv. 2026. PMID: 42018660. doi:10.1182/bloodadvances.2024014082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。